SCHEMBL30777029

SCHEMBL30777029

COc1ccc(-c2ccc3c(=O)n(-c4ccccn4)ncc3c2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GRM7 Q14831 2/20 0.49
▸ SLC11A2 P49281 2/20 0.48
▸ PDCD1 Q15116 1/20 0.46
▸ CD274 Q9NZQ7 1/20 0.46
▸ KDM4E B2RXH2 1/20 0.44
▸ ALDH1A1 P00352 1/20 0.44
▸ HPGD P15428 1/20 0.44
▸ FFAR4 Q5NUL3 4/20 0.43
▸ IRAK4 Q9NWZ3 1/20 0.43
▸ HTR3A P46098 2/20 0.42
▸ PDE5A O76074 1/20 0.42
▸ PDE4A P27815 1/20 0.42
▸ PDE1A P54750 1/20 0.42
▸ PDE1B Q01064 1/20 0.42
▸ PDE4B Q07343 1/20 0.42
▸ PDE4C Q08493 1/20 0.42
▸ PDE4D Q08499 1/20 0.42
▸ PDE3B Q13370 1/20 0.42
▸ PDE1C Q14123 1/20 0.42
▸ PDE3A Q14432 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29175817 1.00 GRM7 (0.49) GRM7SLC11A2PDCD1CD274KDM4E
SCHEMBL30777031 0.91 GRM7 (0.50) GRM7SLC11A2KDM4EALDH1A1HPGD
SCHEMBL29175756 0.91 GRM7 (0.50) GRM7SLC11A2KDM4EALDH1A1HPGD
SCHEMBL29175773 0.87 SLC11A2 (0.43) GRM7SLC11A2PDCD1CD274KDM4E
SCHEMBL30777055 0.87 SLC11A2 (0.43) GRM7SLC11A2PDCD1CD274KDM4E
SCHEMBL10509429 0.86 GRM7 (0.47) GRM7SLC11A2PDCD1CD274KDM4E
SCHEMBL10509418 0.86 GRM7 (0.47) GRM7SLC11A2PDCD1CD274KDM4E
SCHEMBL29175876 0.84 PDE5A (0.45) GRM7PDCD1CD274FFAR4IRAK4
SCHEMBL30777102 0.84 PDE5A (0.45) GRM7PDCD1CD274FFAR4IRAK4
SCHEMBL30777092 0.83 NR3C1 (0.51) GRM7HPGDFFAR4IRAK4HTR3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240327375-A1 SUBSTITUTED HETEROBICYCLIC DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLU7 RECEPTOR ADDEX PHARMA S.A. (CH) 2024-10-03 — — US disclosed
EP-4337643-A1 SUBSTITUTED HETEROBICYCLIC DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLU7 RECEPTOR Addex Pharma S.A (CH) 2024-03-20 — — EP disclosed
CN-117597331-A Substituted heterobicyclic derivatives as MGLU7 receptor negative allosteric modulators 阿德克斯法尔马股份公司 2024-02-23 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240327375-A1 SUBSTITUTED HETEROBICYCLIC DERIVATIVES AS NEGATIVE ALLOSTERIC MODULATORS OF MGLU7 RECEPTOR GRM7, GRM2, GRM1 GRM7 1/4885SLC11A2 4714/4885PDCD1 4029/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback